A collection of feature articles, study abstracts, and additional resources all focused on tardive dyskinesia (TD).
Dr. Eiry Roberts discusses why clinicians should avoid anticholinergics in patients with tardive dyskinesia and opt for VMAT2 inhibitors instead. A manuscript recently published in CNS Drugs explored the use of anticholinergics for patients with drug-induced...
Several clinical trials have tested the efficacy and safety of valbenazine and deutetrabenazine in patients with TD.
Deep brain stimulation offers advantages such as adjustability, reversibility, and the potential for rapid and long-term improvement in tardive dyskinesia.
Annual training and reliable new tools can help physicians improve tardive dyskinesia screening and symptom measurement.
There are approximately 600,000 people in the US who are living with TD—65% of them have not been diagnosed.
The Tardive Dyskinesia Impact Scale complements the Abnormal Involuntary Movement Scale by combining clinician-rated and patient-reported perspectives.
FRIDAY, Jan. 19, 2024 (HealthDay News) -- The Tardive Dyskinesia Impact Scale (TDIS)...
PW QUIZ
The Extrapyramidal Symptom Rating Scale and an abbreviated version of the scale were both validated for measuring the impact of tardive dyskinesia.
Tardive dyskinesia impacts both the patients living with the movement disorder and those who care for them.
Patients consistently felt possible TD impacted their lives, regardless of rating method, suggesting clinician assessments might miss its actual burden.
Researchers proposed a hypothesis linking dysfunctions in the striatum and the dorsal diencephalic connection system (DDCS) to classic tardive dyskinesia (TD).
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
